Chemerin as a Novel Crevicular Fluid Marker of Periodontitis Patients With Type 2 Diabetes Mellitus.

Abstract The objectives of the present study were to determine whether gingival crevicular fluid (GCF) chemerin is a novel predictive marker for chronic periodontitis (CP) patients with and without type 2 diabetes mellitus (T2DM) and to analyse the relationship between chemerin and IL-6 in periodontal health and in CP patients with and without T2DM, as well as to evaluate the effect of non-surgical periodontal therapy on the GCF chemerin levels. Individuals (n = 80) were split into four groups; 20 individuals with systemically and periodontally healthy (CTRL group), 20 patients with T2DM and periodontally healthy (DM-CTRL group), 20 patients with systemically healthy and CP (CP group), 20 patients with CP and T2DM (DM-CP group). Individuals with periodontitis were treated with non-surgical periodontal therapy. Both GCF sampling procedures and clinical periodontal measures were performed prior to treatment and six weeks thereafter. Enzyme-linked immunosorbent assay was utilized to measure both chemerin and IL-6 levels. Greater values for GCF chemerin and IL-6 levels were found in CP groups than in periodontally healthy groups, in DM-CP than in CP group and in DM-CTRL than in CTRL group (P